TOP TEN perturbations for 39269_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39269_at
Selected probe(set): 204127_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39269_at (204127_at) across 6674 perturbations tested by GENEVESTIGATOR:
colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)
Relative Expression (log2-ratio):4.571335Number of Samples:24 / 3
Experimental | colorectal cancer study 4 (recurring) |
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery. | |
Control | adjacent colon tissue (recurring) |
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up. |
T-cell activation study 2 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):3.6719294Number of Samples:2 / 2
Experimental | T-cell activation study 2 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days.. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
tumor supernatant activation study 3 / memory T-cell activation study 1
Relative Expression (log2-ratio):-3.5564585Number of Samples:4 / 3
Experimental | tumor supernatant activation study 3 |
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
Control | memory T-cell activation study 1 |
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs. |
azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-3.3798952Number of Samples:2 / 19
Experimental | azathioprine study 8 (48h) |
HepG2 cells exposed to 250μM azathioprine in DMSO solvent for 48 hours. ATC code: | |
Control | vehicle (DMSO) treated HepG2 cell sample |
HepG2 cells exposed to DMSO solvent for 48 hours. |
colorectal cancer study 4 (non-recurring) / adjacent colon tissue (non-recurring)
Relative Expression (log2-ratio):3.3760757Number of Samples:76 / 18
Experimental | colorectal cancer study 4 (non-recurring) |
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients did not develop metastatic recurrence during follow-up after surgery. | |
Control | adjacent colon tissue (non-recurring) |
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). No metastatic recurrence during follow-up. |
colorectal cancer study 4 (metastatic progression) / adjacent colon tissue (metastatic progression)
Relative Expression (log2-ratio):3.3064213Number of Samples:23 / 4
Experimental | colorectal cancer study 4 (metastatic progression) |
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression. | |
Control | adjacent colon tissue (metastatic progression) |
Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):3.2831383Number of Samples:2 / 2
Experimental | T-cell activation study 4 |
T-cell samples antiCD3 activated for 30hrs. | |
Control | normal resting T-cell sample |
T cells resting for 30h. |
colorectal cancer study 33 (carcinoma; trans. colon) / normal transverse colon tissue
Relative Expression (log2-ratio):3.1770792Number of Samples:2 / 2
Experimental | colorectal cancer study 33 (carcinoma; trans. colon) |
Primary tumor samples derived from the transverse colon of patients with carcinoma. | |
Control | normal transverse colon tissue |
Normal transverse colon tissue samples. |
CH5183284 study 1 (HSC-39) / vehicle (DMSO) treated HSC-39 cell sample
Relative Expression (log2-ratio):-3.108842Number of Samples:2 / 2
Experimental | CH5183284 study 1 (HSC-39) |
Human gastric cell line HSC-39 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:--- | |
Control | vehicle (DMSO) treated HSC-39 cell sample |
Human gastric cell line HSC-39 treated with 0.1% DMSO for 24 hours. |
C. difficile study 1 (TcdA; 24h) / untreated HCT 8 cell sample
Relative Expression (log2-ratio):-3.084179Number of Samples:2 / 2
Experimental | C. difficile study 1 (TcdA; 24h) |
HCT 8 cells were treated with 100 ng/ml Toxin A (TcdA) isolated from Clostridium difficile strain VPI-10643 in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum and 1mM sodium pyruvate for 24 hours. | |
Control | untreated HCT 8 cell sample |
Untreated HCT 8 cell sample cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum and 1mM sodium pyruvate for 24 hours. |